Drugs / Agalsidase alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02956954 | Mar 2017 → Jan 2023 | Fabry disease | University Hospital, Rouen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Agalsidase alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02956954 ↗ |
| Known as | Replagal | “Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)).” NCT02956954 ↗ |
| Modality | Protein / enzyme biologic | “Enzyme replacement therapy (Agalsidase alpha (Replagal®))” NCT02956954 ↗ |